Shane Mesko

Shane Mesko

Auto-generated profile, based on publicly available information

Shane Mesko

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPaul W. Sperduto
Paul W. Sperduto
SMShane Mesko
Shane Mesko
JLJing Li
Jing Li
DCDaniel Cagney
Daniel Cagney
AAAyal Aizer
Ayal Aizer
MMMinesh p Mehta
Minesh p Mehta
PURPOSE: Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS: A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS: Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION: Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).

30 September 2019 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SMShane Mesko
Shane Mesko
HWHe Wang
He Wang
STSamuel Tung
Samuel Tung
CWCongjun Wang
Congjun Wang
DPDario Pasalic
Dario Pasalic
Jack PhanJack Phan
Jack Phan

1 September 2015 in Brachytherapy
Verified
Journal Article
Closed access
SMShane Mesko
Shane Mesko
USUma Swamy
Uma Swamy
SPSang-June Park
Sang-June Park
LBLalaine Borja
Lalaine Borja
JWJason Wang
Jason Wang
MKMitchell Kamrava
Mitchell Kamrava

3 October 2013 in Prostate Cancer
Verified
Journal Article
Open access
PDF file
SMShane Mesko
Shane Mesko
PKPatrick Kupelian
Patrick Kupelian
DDD. Jeffrey Demanes
D. Jeffrey Demanes
JHJaoti Huang
Jaoti Huang
PWPin-Chieh Wang
Pin-Chieh Wang
MKMitchell Kamrava
Mitchell Kamrava
Background:Ki-67 is a robust predictive/prognostic marker in prostate cancer; however, tumor heterogeneity in prostate biopsy samples is not well studied.Methods:Using an MRI/US fusion device, biopsy cores were obtained systematically and by targeting when indicated by MRI. Prostate cores containing cancer from 77 consecutive men were analyzed. The highest Ki-67 was used to determine interprostatic variation. Ki-67 range (highest minus lowest) was used to determine intraprostatic and intralesion variation. Apparent diffusion coefficient (ADC) values were evaluated in relation to Ki-67.Results:Interprostatic Ki-67 mean ± standard deviation (SD) values for NCCN low (L), intermediate (I), and high (H) risk patients were 5.1 ± 3.8%, 7.4 ± 6.8%, and 12.0 ± 12.4% (ANOVAP=0.013). Intraprostatic mean ± SD Ki-67 ranges in L, I, and H risk patients were 2.6 ± 3.6%, 5.3 ± 6.8%, and 10.9 ± 12.3% (ANOVAP=0.027). Intralesion mean ± SD Ki-67 ranges in L, I, and H risk patients were 1.1 ± 0.9%, 5.2 ± 7.9%, and 8.1 ± 10.8% (ANOVAP=0.22). ADC values at Ki-67 > and <7.1% were 860 ± 203 and 1036 ± 217, respectively (P=0.0029).Conclusions:High risk patients have significantly higher inter- and intraprostatic Ki-67 heterogeneity. This needs to be considered when utilizing Ki-67 clinically.


1 November 2020 in Brachytherapy
Verified
Journal Article
Closed access
SMShane Mesko
Shane Mesko
BCBhavana V. Chapman
Bhavana V. Chapman
CTChad Tang
Chad Tang
RKRajat J. Kudchadker
Rajat J. Kudchadker
TBTeresa L. Bruno
Teresa L. Bruno
SFSteven J Frank
Steven J Frank